Directory of Pharmaceuticals Producers in Romania – August 2007

1. Actavis
2. Antibiotice
3. Bio Eel
4. Biofarm
5. Europharm
6. Fabiol
7. Gedeon Richter Romania
8. Helvetica Profarm
9. Labormed-Pharma
10. Laropharm
11. Mark Pharmaceutics
12. Ozone Laboratories
13. Sandoz
14. Santa
15. Sintofarm
16. Terapia Ranbaxy
17. Zentiva
This Companies Directory is produced by FRD Center Romania – www.frdcenter.ro - a privately owned market entry consulting firm based in Romania. The Directory aims to include all relevant producers active in the sector. FRD Center is not liable for any omission in the present document.

FRD Center offers business intelligence and market support for foreign companies interested to enter the Romanian and Bulgarian market as exporters, consultants, investors or joint-ventures.

Since 2000, FRD Center has been the trade consultant for the Irish Government Agency, Enterprise Ireland. Other clients include companies from: Canada, Greece, Ireland, Israel, Lithuania, Norway, Poland, UK, USA, South Africa, Spain etc.

Our services include:

- market reports, investment opportunities assessment, sectorial studies, market briefs
- partners and providers identification, selection and profiling
- commercial due diligence, pre-M&A business support and research
- identification of market opportunities: sourcing, sales etc.
- trade missions, business itineraries, inward buyer missions

FRD Center is the Global Intelligence Alliance Research Partner for Romania and a member of the Global Consulting Network-GCN.

For further details, please contact:
Jackie Bojor, Director of Business Development
FRD Center, Bucharest, Romania –
www.frdcenter.ro
tel: +4021 411 1460; fax: +4021 411 1461
e-mail: europa@frdcenter.ro
1. Actavis

1. General data
Company name: Actavis SRL
Address 1: Bd. Ion Mihalache 11, sector 1, 011171, Bucharest
Phone: +4021 3181777
Fax: +4021 3124499
Address 2: Sos. Odaii 179-185, sector 1, 013604, Bucharest
Phone: +4021 3514567
Fax: +4021 3514565
Web: www.actavis.com.ro
E-mail: inforo@actavis.com
Year of establishment: 1991
Ownership: Actavis Iceland

2. Financial data

<table>
<thead>
<tr>
<th>Year/Category</th>
<th>Turnover (mil. EUR)</th>
<th>Employees</th>
<th>Net profit (mil. EUR)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2005</td>
<td>67.8</td>
<td>107</td>
<td>11.1</td>
</tr>
<tr>
<td>2004</td>
<td>69.4</td>
<td>112</td>
<td>5.2</td>
</tr>
<tr>
<td>2003</td>
<td>64.0</td>
<td>142</td>
<td>4.2</td>
</tr>
</tbody>
</table>

Type of investment

<table>
<thead>
<tr>
<th>Construction of a production facility near Bucharest</th>
<th>already done</th>
<th>announced</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>50 million EUR (2007 - 2009)</td>
</tr>
</tbody>
</table>

Total assets (2005): 25.9 million EUR

3. Key persons

<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
<th>Phone</th>
<th>Email</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mr. Laurentiu Scheusan</td>
<td>General Director</td>
<td>+4021 3514567</td>
<td><a href="mailto:lscheusan@actavis.com">lscheusan@actavis.com</a></td>
</tr>
<tr>
<td>Mr. Mihai Dimitriu</td>
<td>Commercial Manager</td>
<td>+40745985009 (mobile)</td>
<td><a href="mailto:mdimitriu@actavis.com">mdimitriu@actavis.com</a></td>
</tr>
<tr>
<td>Mr. Razvan Ciopraga</td>
<td>Marketing Manager</td>
<td>+4021 3514567</td>
<td><a href="mailto:rciopraga@actavis.com">rciopraga@actavis.com</a></td>
</tr>
<tr>
<td>Ms. Irina Gheorghiade</td>
<td>Corporate Relations Director</td>
<td>+4021 3514567</td>
<td><a href="mailto:igheorghiade@actavis.com">igheorghiade@actavis.com</a></td>
</tr>
<tr>
<td>Ms. Ana Maria Draganica</td>
<td>Corporate Relations Officer</td>
<td>+40 21 3514567</td>
<td><a href="mailto:adraganica@actavis.com">adraganica@actavis.com</a></td>
</tr>
</tbody>
</table>
4. **Main brands**: Sindaxel®, Episindan®, Antifolan®, Diamalin®, Flutasin®, Folcasin®, Megesin®, Rogluten®, Sindronat®, Tamoneprin®

5. **Brief profile**
Actavis acquired in March 2006 the company Sindan Pharma, the biggest producer of cancer drugs in Romania, in a transaction of 147.5 million EUR. Actavis Romania recorded in the first trimester of 2007 incomes of 11.6 million EUR, this representing an increase by 25% compared to the similar period of 2006. The company recorded in 2006 a turnover of 95 million EUR, out of which 10 million EUR were represented by exports.

Actavis launched seven products on the domestic market in 2006 and plans to introduce another 15 new products during 2007. According to Actavis sources, the Romanian market generates 7% of the incomes registered by the Group in the Central and Eastern Europe and Asia, excluding the results of the distribution division.

Actavis will start during 2007 the construction of a production facility near Bucharest. The first stage of the investments will become operational in 2009. The production facility will be built on three modules, in order to allow the further expansion. The first module will have the production capacity of about 6 - 8 million units per year. After the construction of the other two modules, the production capacity could double or triple. The new production unit will produce exclusively cancer drugs.